Social Media Ideas for Amgn

Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

Amyloidosis Continues To Fight Back

Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases

ANC

ANC Anonymous (not verified) Tue, 08/04/2026 - 21:28 field_thread_url https://cafepharma.com/boards/threads/anc.712901/ board name...

argenx SE (ARGX) Forte Biosciences, Inc. - M&A Call - Slideshow

Syndax

Syndax Anonymous (not verified) Sun, 07/19/2026 - 15:19 field_thread_url https://cafepharma.com/boards/threads/syndax.695213/ board name...

Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know

argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go

Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug

Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca...

<![CDATA[Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion]]>

<![CDATA[argenx Acquires Forte Biosciences for $2.2 Billion]]>

Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel

Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript

Amgen drops early-stage obesity drug, upping pressure on MariTide

Amgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice of the massive weight loss market onto the shoulders of phase 3 candidate MariTi...

Genmab

Genmab Anonymous (not verified) Mon, 07/13/2026 - 12:14 field_thread_url https://cafepharma.com/boards/threads/genmab.680642/ board name...

BioMarin to acquire Alesta Therapeutics for up to $490 million

Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

Amgen’s $74 Million Securities Deal Puts Tax Disclosure Timing in Focus

Amgen has agreed to pay $74 million to resolve a shareholder class action in the Southern District of New York alleging the company waited too long to disclose a potential IRS tax...

argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?